The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Trial end date:
2017-07-04
Target enrollment:
Participant gender:
Summary
This is a multinational, multicenter, randomized, double-blind, parallel-group,
placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and
tolerability of two doses of oral administration of laquinimod in participants with RRMS. The
study has 2 periods: Period 1, the double-blind, placebo-controlled period (up to 24 months)
and Period 2, the active treatment period (24 months).
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries